Outlook Therapeutics Announces LYTENAVA™ (bevacizumab-vikg), Anticipated Brand Name for ONS-5010, If Approved Bay Street 5 years ago Outlook Therapeutics intends to market ONS-5010 as LYTENAVA™Bay Street News